The relationships between EGFR tyrosine kinase inhibitor resistance, Relaxin signaling pathway, AGE-RAGE signaling pathway, and prostate cancer have been widely investigated and reported in the previous works75–77. Here, RENBP is linked to prostate carcinoma.